Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?

Overview

Journal Vaccines (Basel)

Date 2021 Oct 26

PMID 34696251

Citations 3

Authors

Massimo Vitale

Monica Parodi

Affiliations

Soon will be listed here.

Abstract

Natural Killer (NK) cells are becoming an ever more promising tool to design new anti-tumor strategies. However, two major issues are still a challenge to obtain versatile and effective NK-based therapies: the way to maximize the persistency of powerful NK effectors in the patient, and the way to overcome the multiple escape mechanisms that keep away or suppress NK cells at the tumor site. In this regard, targeting the hypoxia-inducible factors (HIFs), which is important for both tumor progression and immune suppression, may be an opportunity. Especially, in the context of the ongoing studies focused on more effective NK-based therapeutic products.

Citing Articles

Hypoxia drives the formation of lung micropapillary adenocarcinoma-like structure through hypoxia-inducible factor-1α.

Umeda D, Harada A, Motooka D, Tahara S, Kurashige M, Kido K Sci Rep. 2024; 14(1):31642.

PMID: 39738173 PMC: 11685966. DOI: 10.1038/s41598-024-80280-x.

Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells.

Parodi M, Centonze G, Murianni F, Orecchia P, Andriani F, Roato I J Immunother Cancer. 2024; 12(3).

PMID: 38458638 PMC: 10921513. DOI: 10.1136/jitc-2023-007895.

When a Friend Becomes Your Enemy: Natural Killer Cells in Atherosclerosis and Atherosclerosis-Associated Risk Factors.

Palano M, Cucchiara M, Gallazzi M, Riccio F, Mortara L, Gensini G Front Immunol. 2022; 12:798155.

PMID: 35095876 PMC: 8793801. DOI: 10.3389/fimmu.2021.798155.

References

Berrien-Elliott M, Cashen A, Cubitt C, Neal C, Wong P, Wagner J . Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. Cancer Discov. 2020; 10(12):1854-1871. PMC: 7710923. DOI: 10.1158/2159-8290.CD-20-0312. View

Elliott J, Wahle J, Yokoyama W . MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med. 2010; 207(10):2073-9. PMC: 2947074. DOI: 10.1084/jem.20100986. View

Gleason M, Verneris M, Todhunter D, Zhang B, McCullar V, Zhou S . Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012; 11(12):2674-84. PMC: 3519950. DOI: 10.1158/1535-7163.MCT-12-0692. View

Zheng X, Qian Y, Fu B, Jiao D, Jiang Y, Chen P . Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat Immunol. 2019; 20(12):1656-1667. DOI: 10.1038/s41590-019-0511-1. View

Corzo C, Condamine T, Lu L, Cotter M, Youn J, Cheng P . HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010; 207(11):2439-53. PMC: 2964584. DOI: 10.1084/jem.20100587. View

Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D . Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol. 2016; 139(1):335-346.e3. DOI: 10.1016/j.jaci.2016.04.025. View

Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud V . Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A. 2003; 100(15):8856-61. PMC: 166403. DOI: 10.1073/pnas.1431057100. View

Mas-Bargues C, Sanz-Ros J, Roman-Dominguez A, Ingles M, Gimeno-Mallench L, El Alami M . Relevance of Oxygen Concentration in Stem Cell Culture for Regenerative Medicine. Int J Mol Sci. 2019; 20(5). PMC: 6429522. DOI: 10.3390/ijms20051195. View

Wrangle J, Velcheti V, Patel M, Garrett-Mayer E, Hill E, Ravenel J . ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018; 19(5):694-704. PMC: 6089612. DOI: 10.1016/S1470-2045(18)30148-7. View

10.

Sun J . Re-educating natural killer cells. J Exp Med. 2010; 207(10):2049-52. PMC: 2947064. DOI: 10.1084/jem.20101748. View

11.

Joncker N, Shifrin N, Delebecque F, Raulet D . Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med. 2010; 207(10):2065-72. PMC: 2947079. DOI: 10.1084/jem.20100570. View

12.

Pfeifer C, Highton A, Peine S, Sauter J, Schmidt A, Bunders M . Natural Killer Cell Education Is Associated With a Distinct Glycolytic Profile. Front Immunol. 2019; 9:3020. PMC: 6305746. DOI: 10.3389/fimmu.2018.03020. View

13.

Sarvaria A, Jawdat D, Madrigal J, Saudemont A . Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications. Front Immunol. 2017; 8:329. PMC: 5362597. DOI: 10.3389/fimmu.2017.00329. View

14.

Chiu D, Tse A, Xu I, Cui J, Lai R, Li L . Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017; 8(1):517. PMC: 5593860. DOI: 10.1038/s41467-017-00530-7. View

15.

Velasquez S, Killian D, Schulte J, Sticht C, Thiel M, Lindner H . Short Term Hypoxia Synergizes with Interleukin 15 Priming in Driving Glycolytic Gene Transcription and Supports Human Natural Killer Cell Activities. J Biol Chem. 2016; 291(25):12960-77. PMC: 4933215. DOI: 10.1074/jbc.M116.721753. View

16.

Fallah J, Rini B . HIF Inhibitors: Status of Current Clinical Development. Curr Oncol Rep. 2019; 21(1):6. DOI: 10.1007/s11912-019-0752-z. View

17.

Shohet R, Garcia J . Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia. J Mol Med (Berl). 2007; 85(12):1309-15. DOI: 10.1007/s00109-007-0279-x. View

18.

Baginska J, Viry E, Paggetti J, Medves S, Berchem G, Moussay E . The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol. 2014; 4:490. PMC: 3872331. DOI: 10.3389/fimmu.2013.00490. View

19.

Sivori S, Meazza R, Quintarelli C, Carlomagno S, Della Chiesa M, Falco M . NK Cell-Based Immunotherapy for Hematological Malignancies. J Clin Med. 2019; 8(10). PMC: 6832127. DOI: 10.3390/jcm8101702. View

20.

Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari M . Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. Eur J Immunol. 2013; 43(10):2756-64. DOI: 10.1002/eji.201343448. View